Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week low during trading on Wednesday . The company traded as low as GBX 5 and last traded at GBX 5, with a volume of 140799 shares changing hands. The stock had previously closed at GBX 5.25.
Allergy Therapeutics Trading Down 4.8%
The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The stock has a market cap of £316.63 million, a P/E ratio of -5.15, a PEG ratio of -30.70 and a beta of 0.87. The firm’s fifty day moving average price is GBX 7.13 and its two-hundred day moving average price is GBX 9.46.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Read More
- Five stocks we like better than Allergy Therapeutics
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
